8-KShareholder Matters

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 10, 2013)

Filed June 10, 2013For Securities:ALNY

Summary

This 8-K filing from Alnylam Pharmaceuticals, Inc. reports on the results of its 2013 Annual Meeting of Stockholders held on June 6, 2013. The key takeaway for investors is the overwhelmingly positive shareholder support for critical corporate governance and executive matters. The company successfully re-elected all three Class III directors, demonstrating confidence in the current leadership. Additionally, shareholders approved a significant increase in the number of shares authorized under the 2009 Stock Incentive Plan, which is crucial for future employee compensation and retention, a vital aspect for a growth-oriented biotechnology company.

Key Highlights

  • 1Three Class III directors were re-elected, with substantial "For" votes, indicating shareholder confidence in the board's leadership.
  • 2The 2009 Stock Incentive Plan was approved as amended, increasing authorized shares from 2,200,000 to 5,900,000, supporting future equity-based compensation.
  • 3Shareholders approved, in an advisory, non-binding vote, the compensation of the company's named executive officers with strong majority support.
  • 4The appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2013, was ratified with near-unanimous approval.
  • 5A significant number of shares (62,139,891) were issued and outstanding as of the record date (April 19, 2013).

Frequently Asked Questions

This Form 8-K was filed to report the results of Alnylam Pharmaceuticals, Inc.'s 2013 Annual Meeting of Stockholders, which took place on June 6, 2013. It details the outcomes of various shareholder votes.

Yes, all three Class III directors who stood for re-election (Victor J. Dzau, M.D., Steven M. Paul, M.D., and Kevin P. Starr) were re-elected by shareholders. The voting results showed strong support for each nominee.

Shareholders approved the amendment to the 2009 Stock Incentive Plan, which increases the total number of shares authorized for issuance under the plan from 2,200,000 to 5,900,000. This is important for the company's ability to grant equity compensation.

Yes, the appointment of PricewaterhouseCoopers LLP as the company's independent auditors for the fiscal year ending December 31, 2013, was ratified by the shareholders with very high approval.